<DOC>
	<DOCNO>NCT02794285</DOCNO>
	<brief_summary>The purpose study characterise long-term safety tolerability intravenous anifrolumab .</brief_summary>
	<brief_title>Long Term Safety Anifrolumab Adult Subjects With Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This Phase 3 , multicentre , multinational , randomised , double-blind , placebo-controlled extension study characterise long term safety tolerability intravenous treatment regimen anifrolumab versus placebo subject moderately severely active systemic lupus erythematosus complete Phase 3 study ( D3461C00004 D3461C00005 ) 52-week double-blind treatment period .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>1 . Subjects qualify received investigational product ( anifrolumab placebo ) complete treatment period Studies D3461C00004 D3461C00005 ( Week 52 ) 2 . Adequate peripheral venous access 3 . Females intact cervix documentation Pap smear document malignancy within 90 day Day 1/Visit 1 . Since access Pap smear may vary country , Sponsor recommend local guideline obtain Pap smear subject received immunomodulators immunosuppressive treatment follow . 4 . Meets follow TB criterion : 1 . Negative QuantiFERONÂ®TB Gold [ QFTG ] test result TB obtain study central laboratory Week 52 Studies D3461C00004 D3461C00005 ; OR 2 . Newly positive QFTG test result Week 52 Studies D3461C00004 D3461C00005 study central laboratory . A chest xray must perform . If chest xray show evidence active TB , subject symptom medical history consistent active TB , subject must retest . If retest positive , subject must start prophylaxis within 30 day randomisation prior second dose investigational product ( Visit 2/Week 4 ) ; OR 3 . Positive newly positive QFTG test Week 52 Studies D3461C00004 D3461C00005 . The subject must diagnose latent TB must documentation confirm initiation appropriate treatment OR initiate treatment latent TB within 30 day randomization , prior second dose investigational product administration ( Visit 2/Week 4 ) 4 . Newly indeterminate ( confirm retest ) indeterminate newly indeterminate QFTG test result Week 52 Studies D3461C00004 D3461C00005 study central laboratory ongoing QFTG test TB accord Study Plan 5 . In opinion Investigator , subject must able comprehend ICF protocol relate assessment 1 . Receipt follow within last 60 day : 1 . Azathioprine &gt; 200 mg/day 2 . Mycophenolate mofetil/mycophenolic acid &gt; 2.0 g/day 3 . Oral , subcutaneous , intramuscular methotrexate &gt; 25 mg/week 2 . Receipt investigational product ( small molecule biologic agent anifrolumab ) within 4 week 5 halflives prior Day 1/Visit 1 , whichever great 3 . Receipt follow : 1 . Any live attenuate vaccine within 8 week prior Day 1/Visit 1 ( administration kill vaccine acceptable , Sponsor recommend Investigators ensure subject date require vaccination , include influenza [ inactivated/recombinant ] vaccine prior study entry ) 2 . Bacillus CalmetteGuerin ( BCG ) vaccine end Studies D3461C00004 D3461C00005 Day 1/Visit 1 4 . Active severe SLEdriven renal neuropsychiatric disease 5 . Any underlying condition predisposes subject infection , include history of/current human immunodeficiency virus ( HIV ) infection 6 . Subjects Hepatitis B core antibody ( HBcAb ) positivity enrolment Studies D3461C00004 D3461C00005 test every 3 month Hepatitis B virus ( HBV ) DNA . To remain eligible LTE study , subject HBV DNA level must remain low limit quantitation ( LLOQ ) per central laboratory . 7 . Opportunistic infection require hospitalisation parenteral antimicrobial treatment within 3 year Day 1/Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lupus Erythematosus , Systemic Autoimmune Diseases , Connective Tissue Diseases , Immune System Diseases</keyword>
</DOC>